WHO Consultation on RSV Vaccine Development  
23-24 March 2015  
Starling Hotel and Conference Centre, Geneva, Switzerland

List of Participants

Narendra Kumar Arora, Executive Director, The INCLEN Trust International, New Delhi, India

Louis Bont, Pediatrician Infectiologist, Wilhelmina Children's Hospital, Netherlands

Harry Campbell, Department of Public Health Sciences, Edinburgh, United Kingdom of Great Britain & Northern Ireland

Peter Collins, Chief, RNA Viruses, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, United States of America

Janet Englund, Professor, Department of Paediatrics, Seattle Children's Hospital, University of Washington, Seattle, United States of America

Barney S. Graham, Senior Investigator, Chief, Clinical Trials Core, Chief, Viral Pathogenesis Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, United States of America

Eric Karikari-Boateng, Head of Laboratory Services Department, Food and Drugs Authority Ghana, Accra, Ghana

Ruth Karron, Professor, International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

David Kaslow, Vice President, Product Development (Chair PDVAC), PATH, Program for Appropriate Technology in Health, Seattle, United States of America

Shabir A. Madhi, Executive Director, National Institute for Communicable Diseases, Division of NHLS, National Institute for Communicable Diseases, Johannesburg, South Africa

Harish Nair, Senior Research Fellow, Centre for Population Health Sciences, Edinburgh, Scotland, United Kingdom of Great Britain & Northern Ireland

Nienke Scheltema, Wilhelmina Children's Hospital, Netherlands

Patricia Njuguna, Paediatrician, KEMRI Wellcome Trust Collaborative Research Programme, Kilifi, Kenya

James Nokes, Chairman Epidemiology and Demography Department, Kilifi, Kenya

Fernando Pollack, Founding Director, Fundación INFANT, Buenos Aires, Argentina
Mair Powell, Medicines and Healthcare products Regulatory Agency, London, SW1W 9SZ United Kingdom of Great Britain & Northern Ireland

Claire-Anne Siegrist, Head, WHO Collaborating Centre for Neonatal Vaccinology, Department of Pediatrics & Pathology-Immunology, Centre Médical Universitaire, Genève, Switzerland

Eric A.F. Simoes, The University of Colorado Health Sciences Center and the Children's Hospital, Section of Pediatric Infectious Diseases, Denver, United States of America

Peter Smith, MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain & Northern Ireland

James Southern, Advisor to Medicines Control Council in South Africa, Chair DCVRN, Medicines Control Council, Simon's Town, South Africa

OBSERVERS

Allison August, Head of Maternal Immunization, Novavax Inc., Gaithersburg, United States of America

Ilse Dieussaert, Lead Clinician on RSV Programme, GlaxoSmithKline Biologicals, Wavre, W98 B-1300 Belgium

Filip Dubovsky, Vice President, Clinical Development, Therapeutic Area Head, Vaccines, MedImmune, Gaithersburg, United States of America

Amy Fix, VP and Head of Novavax Regulatory Affairs, Novavax Inc., Gaithersburg, 20878 MD, United States of America

Jorge Flores, Clinical Lead, RSV Vaccine Project, PATH, Seattle United States of America

Gregory Glenn, Senior Vice President of Research and Development, Maryland, United States of America

Pamela Griffin, Senior Director, Clinical Department, MedImmune, Gaithersburg, MD 20878, United States of America

Gerco Haars, Senior Manager Epidemiology, GlaxoSmithKline Biologicals, Rixensart, 1330 Belgium

Deborah Higgins, Senior Technical Officer, Vaccine Development Global Program, PATH, Seattle, United States of America

Keith Paul Klugman, Director, Pneumonia, The Bill and Melinda Gates Foundation, Seattle, United States of America
Mike McCarthy, MedImmune, Gaithersburg, United States of America

Jeff Roberts, Food and Drug Administration, CBER, Bethesda, United States of America
(by phone)

Jean-François Toussaint, Director, Vaccine Project Leader, Discovery & Early Development Portfolio, Vaccines Discovery & Development, GlaxoSmithKline Biologica, Rixensart, 1330 Belgium

Alan Shapiro, Food and Drug Administration, CDER, Bethesda, United States of America
(by phone)

Niteen Wairagkar, Senior Program Officer, Infectious Diseases, Global Health Program, The Bill and Melinda Gates Foundation, Seattle, WA 98102, United States of America

WHO SECRETARIAT

Ahmed Bellah, Regulatory Systems Strengthening, HIS/RSS, WHO-HQ, Geneva, Switzerland

Terry Gail Besselaar, Influenza, Hepatitis and PIP Framework, HIP/HSE, WHO-HQ, Geneva, Switzerland

Brigitte Giersing, Initiative for Vaccine Research, FWC/IVB, WHO-HQ, Geneva, Switzerland

Ivana Knezevic, Technologies Standards and Norms, HIS/EMP, WHO HQ, Geneva, Switzerland

Kayvon Modjaard Initiative for Vaccine Research, FWC/IVB, WHO HQ, Geneva, Switzerland

Vasee Moorthy, Initiative for Vaccine Research, FWC/IVB, WHO HQ, Geneva, Switzerland

Wenqing Zhang, Influenza, Hepatitis and PIP Framework, HIP/HSE, WHO-HQ, Geneva, Switzerland

Tiequn Zhou, Technologies Standards and Norms, HIS/TSN, WHO-HQ, Geneva, Switzerland